Quick Answer
GOLDENWELL BIOTECH, INC. reported Operating Income Loss of -$123.1 thousand for the year ending 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -6.3% in Operating Income Loss from 2023 to 2024.
- This data is from GOLDENWELL BIOTECH, INC.'s annual report (Form 10-K), filed with the SEC on May 15, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: -$88.7 thousand | Q1 2022: -$33.4 thousand | Q2 2022: -$26.8 thousand | Q3 2022: -$4.6 thousand | Q4 2022: -$920.3 thousand | Q1 2023: -$33.6 thousand | Q2 2023: -$27.1 thousand | Q3 2023: -$35.4 thousand | Q4 2023: -$20.8 thousand | Q1 2024: -$29.0 thousand | Q2 2024: -$47.8 thousand | Q3 2024: -$21.0 thousand | Q1 2025: -$32.3 thousand | Q2 2025: -$3.1 thousand | Q3 2025: -$5.9 thousand.
- Over the full 4 years of available data (2021 to 2024), GOLDENWELL BIOTECH, INC.'s Operating Income Loss has declined by 4.1%.
- Historical annual values: Fiscal year 2024: -$123.1 thousand | Fiscal year 2023: -$115.8 thousand | Fiscal year 2022: -$985.1 thousand | Fiscal year 2021: -$118.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: